Cellular and Molecular Analysis in LAM Disease
A study aimed to define the clinical course of lymphangioleiomyomatosis (LAM) and investigate its cellular and molecular pathogenesis. The researchers planned to determine the proliferation mechanisms of smooth muscle cells, evaluate protein and genetic factors' contributions, and assess TSC genes' roles in LAM.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
Why it matters
Understanding the molecular basis of smooth muscle cell proliferation in LAM could improve insights into related diseases and potentially guide more effective therapies in the future.
What this does not prove
No results are posted; findings from this study are not yet available, and planned enrollments do not reflect actual outcomes.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- No
- Research areas
- Not classified
Original sources
- Trial registrationStudy of the Disease Process of Lymphangioleiomyomatosis ↗
Supporting passages (5)
subjectsIndividuals with pulmonary lymphangioleiomyomatosis develop severe destructive lung disease.
regulatory approval"isFdaRegulatedDevice": false
primary endpointThis study is designed to (a) define the clinical course of the disease and (b) elucidate the pathogenesis of the disease at the cellular and molecular levels, in order to develop more effective therapy.
findings"description": "To define the molecular basis of the remarkable proliferation of immature appearing smooth muscle cells, which is the cause of many of the clinical manifestations, and perhaps thereby to improve our understanding of the mechanism of smooth muscle cell proliferation in other diseases, e.g., interstitial lung diseases, asthma, atherosclerosis, hypertension, and post-angioplastic coronary restenosis.
limitationsPlanned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.